Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded mixed, with the Dow Jones gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.
Reported Late Thursday, G1 Therapeutics Announces Pricing Of $50.05M Public Offering Of 7.7M Shares Of Common Stock At A Price Of $6.50/Share
G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the pricing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.
G1 Therapeutics Announces Investigator Initiated Study Of Trilaciclib And Lurbinectedin In Patients With Extensive Stage Small Cell Lung Cancer
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it is supporting a Phase 2 investigator initiated study (ISS) of trilaciclib and lurbinectedin in patients
G1 Therapeutics Granted US Patent #11,395,821 Treatment of EGFR-driven cancer with fewer side effects
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=3594&f=G&l=50&d=PTXT&p=72&S1=20220726&OS=20220726&RS=20220726
COSELA (Trilaciclib Hydrochloride For Injection) Now Approved In China To Decrease The Incidence Of Chemotherapy-Induced Myelosuppression In Patients With Extensive-Stage Small Cell Lung Cancer
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
RESEARCH
